for More

Stay informed about CLN2 disease resources, including a free epilepsy gene panel testing program that may help you diagnose CLN2 early.


Click here to watch on-demand, a no–cost, live, educational webinar discussing the importance of early genetic testing in pediatric epilepsy - Insights from a CLN2 disease experience.

CA/CLN2/0060 Nov 2019

The Natural Course of CLN2 Disease is Rapid

Children with CLN2 disease commonly experience a complete loss of cognitive abilities, motor function, and vision within the first decade of life.1,2

Earlier Diagnosis is Critical & Testing is Straightforward

Given the rapid rate of progression, early diagnosis is essential to ensure that families can benefit from CLN2-specific management strategies and maximize quality time.3,4

Optimize Care With CLN2 Disease Management Strategies

Experts have identified CLN2 disease–specific management strategies that can greatly impact patient care and quality of life.4

1. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases – clinical perspectives. Biochimica et Biophysica Acta. 2013;1832:1801-1806. 2. Mole SE, Williams RE. Neuronal ceroid-lipofuscinoses. 2001 Oct 10 [Updated 2013 Aug 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [internet]. Seattle, WA: University of Washington; 1993-2016. 3. Schulz A, Cohen-Pfeffer JL, Crystal R, et al. Neuronal ceroid lipofuscinosis-2 (CLN2) disorder, a type of Batten disease caused by TPP1 enzyme deficiency: current knowledge of the natural history from international experts. Poster session presented at: The Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium; September 2015; Lyon, France. 4. Williams RE, Adams HR, Blohm M, et al. Expert opinion on the management of CLN2 disease. Poster session presented at: The 12th Annual WORLD Symposium; February – March 2016; San Diego, CA.